Both parties will work together to analyze the "biology and genetics of aging" to further understand diseases, such as hypertension and atherosclerosis, and utilize the research findings to formulate treatments, according to the press release the Broad Institute published on March 17.
Said Calico CEO Art Levinson in a statement, "This alliance is a key part of Calico's strategy to bring the best cutting-edge science to bear on problems of aging. The Broad Institute is one of the nation's preeminent research organizations whose outstanding research has repeatedly revealed fundamental mechanisms of the biology and genetics of disease."
The Broad Institute, a joint venture between Harvard and MIT, is an 11-year-old establishment filled with scientists studying the underlying causes of cancer, infectious diseases, and other pathogens.
Calico, though, remains shrouded in mystery. Google introduced the company to the world in September 2013 with a mission to "cure death."
Details are still vague on how Calico will accomplish this goal.
However, this agreement with the Broad Institute is the second research and development partnership Calico has constructed within its brief existence.
Last year, the startup struck a multi-million dollar R&D deal with Chicago-based drugmaker AbbVie to find potential cures for cancer and Alzheimer's.
No financial details were disclosed in this announcement.